𝘊𝘭𝘰𝘴𝘵𝘳𝘪𝘥𝘪𝘰𝘪𝘥𝘦𝘴 𝘥𝘪𝘧𝘧𝘪𝘤𝘪𝘭𝘦 infection (CDI)

General Information

Clostridioides difficile (C. difficile) is an anaerobic bacterium, widely distributed in soil and the intestinal tracts of animals.

Currently, no vaccine is licensed for the prevention of CDI.

Transmission

The transmission of C. difficile can be patient-to-patient, via contaminated hands of healthcare workers or by environmental contamination.

Symptoms

The clinical spectrum of C. difficile infection (CDI) ranges from mild diarrhoea to severe life-threatening pseudomembranous colitis.

Epidemiology

1 in 11 people over age 65 diagnosed with a healthcare-associated C. difficile infection dies within one month.

Nearly 124,000 healthcare-associated C. difficile infections (CDIs) occur annually in acute care hospitals in the EU/EEA, and 3,700 deaths.

Vaccines Pipeline

2
Vaccines in
the pipeline

TECHNOLOGY PLATFORMS

Toxoid vaccine (2)

DEVELOPMENT PHASES

Phase II (1)
Phase III (1)

TRIAL POPULATION

Paediatric + Adults + Older adults (1)
Older adults (1)

Sources:
Clostridium difficile infections – Facts and surveillance. 2023. Available from: https://www.ecdc. europa.eu/en/clostridium-difficile-infections/facts.
C. diff (Clostridioides difficile). 2024. Available from: https://www.cdc.gov/c-diff/index.html.
[Accessed: August 2024]